Assembly Biosciences — Third Quarter 2026 Earnings Summary

Assembly Biosciences initiated a Phase 2 clinical study for its drug ABI-6250 in patients with chronic hepatitis delta virus infection and received FDA approval to proceed with a Phase 2 study for cholestatic liver diseases. The company exercised its option to share 40% of U.S. development costs and profits for the HSV helicase primase inhibitor program under its collaboration with Gilead Sciences. Assembly Biosciences received a $75 million collaboration extension fee from Gilead, bringing its total cash, cash equivalents, and marketable securities to $314.3 million as of September 30, 2026, which is projected to fund operations into 2029. For the third quarter of 2026, the company reported revenue of $3.0 million from collaborative research and a net loss of $20.3 million.